Ray D. Page
Center for Cancer and Blood Disorders · 122 works · 3,904 citations · h-index 27
Top works
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment Model
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
- Primary hepatic lymphoma
- American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology
- Telehealth in Oncology: ASCO Standards and Practice Recommendations
- PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer
- Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
- Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
- Opioids and Cancer Pain: Patients’ Needs and Access Challenges
- Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
- Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology
- A Pathway Through the Bundle Jungle
- Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).
- Pernicious Anemia: Presentations Mimicking Acute Leukemia
- Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.